Xtant Medical Gains $10.7 Million to Focus on Biologics After Asset Sale to Companion Spine
- Xtant Medical Holdings secures $10.7 million from Companion Spine, enhancing focus on its biologics business.
- The funds will reduce long-term debt and improve cash liquidity for Xtant Medical.
- Xtant aims to innovate in orthopedic and spinal surgical markets while prioritizing patient care.
Xtant Medical Secures $10.7 Million from Companion Spine, Enhancing Focus on Biologics Business
Xtant Medical Holdings, Inc. announces a significant financial boost with the receipt of $10.7 million from Companion Spine. This payment stems from the acquisition of Xtant's Coflex® assets and Paradigm OUS businesses, which was finalized in December 2025, raising the total consideration for the divestitures to $21.4 million. The financial transaction is composed of $8.2 million addressing an unsecured promissory note, inclusive of accrued interest, while the remaining $2.2 million involves adjustments related to working capital and various purchase price considerations.
Sean Browne, the President and CEO of Xtant Medical, expresses confidence in the completed transaction, signifying a strategic transition of its assets to Companion Spine, which is recognized as a leader in the neuro-musculoskeletal sector. This shift is pivotal for Xtant, as it allows the company to intensify its focus on its higher-margin biologics business. The divestiture is not merely a financial maneuver; it reflects Xtant’s commitment to its core mission of enhancing patients' lives through innovative medical solutions.
The influx of funds is expected to bolster Xtant Medical's financial standing by reducing long-term debt and improving cash liquidity. The company is dedicated to designing and commercializing a wide range of orthobiologics aimed at chronic and surgical wound care, alongside spinal implant systems. By divesting certain assets, Xtant is poised to streamline operations, ensuring that resources are allocated efficiently and effectively to develop its advanced product portfolio while upholding its commitment to integrity in service to its customers.
In addition to the financial impacts, Xtant Medical is continuously focused on innovation within the orthopedic and spinal surgical markets. By reallocating resources and refining its business strategies, the company aims to enhance its product offerings and maintain a competitive edge in an evolving medical landscape. The leadership at Xtant signals that this strategic transition is part of a larger vision to prioritize patient care and transformative medical technology.
Furthermore, the recent developments indicate Xtant Medical's commitment to adapting to market demands and aligning its operations with best practices in the industry. The ongoing emphasis on cash liquidity and long-term financial stability positions the company favorably for future growth and collaborations within the medical technology sector.